Daiichi Sankyo Company, Limited (DSKYF) Stock Price & Analysis
Daiichi Sankyo Company, Limited (DSKYF) — price $17.72 (0.00%), as of the Nov 19, 2026 trading session; market cap $32.3B.
Educational signal · not a buy or sell recommendation · How to read this
Daiichi Sankyo Company, Limited · DSKYF · Healthcare · Drug Manufacturers - General
Daiichi Sankyo Company, Limited operates as a global pharmaceutical powerhouse, dedicated to the research, development, manufacturing, and worldwide commercialization of a wide array of medicinal products.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $17.72 | |
| Change on the day | 0.00% | |
| 52-week range | $13.85–$25.75 | |
| Market capitalisation | $32.3B | — |
| Price / earnings (trailing) | 18.00 | |
| Shares traded on the day | 773 | |
| Beta (volatility vs the S&P 500) | 0.12 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Daiichi Sankyo Company (DSKYF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Daiichi Sankyo Company (DSKYF), and what does it report?
Short answer · as of
Daiichi Sankyo researches, manufactures and commercializes prescription medicines worldwide from its Tokyo base.
Research dated 2026-09-12.
Its products span oncology, cardiovascular and neurological care, pain, diabetes, bone health, infections and other conditions, complemented by vaccines, consumer brands, active ingredients and chemical intermediates.
The reported results therefore measure a diversified pharmaceutical group rather than a pure oncology developer. Enhertu is the distinctive growth platform, but consolidated revenue also includes mature medicines and brands such as Lulu, Loxonin S, Transino and Minon; the income statement does not isolate those economics in the figures shown here.
What do the latest results show for Daiichi Sankyo Company (DSKYF)?
Short answer · as of
The most recent reported quarter, Q2 FY2027, carried revenue of ¥599.02B. Against analyst estimates the company has EPS beat 5 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2027 | ¥599.02B | ¥85.35B | ¥46.15 (diluted) |
| Q1 FY2027 | ¥570.58B | ¥68.14B | ¥37.13 (diluted) |
| Q4 FY2026 | ¥593.30B | ¥42.70B | ¥23.97 (diluted) |
| Q3 FY2026 | ¥558.59B | ¥86.71B | ¥46.80 (diluted) |
What are the financial strengths and risks for Daiichi Sankyo Company (DSKYF)?
Short answer · as of
The distress and quality screens read Altman Z 2.93 · Piotroski F 6. Trailing ratios: ROE 17.6% · ROA 4.6% · current ratio 2.81.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held DSKYF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported DSKYF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Daiichi Sankyo Company (DSKYF)?
- Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results
- Daiichi Sankyo Gets $75M Milestone From AstraZeneca After EU Approves Enhertu For Adjuvant HER2 Positive Early Breast Cancer; DESTINY-Breast05 Showed 53% Lower Recurrence Or Death Risk Versus T-DM1
- Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO
Daiichi Sankyo Company Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.
What makes Enhertu important to Daiichi Sankyo?
Enhertu places an antibody-drug conjugate at the center of Daiichi Sankyo’s oncology offering. Its commercial contribution sits within a much broader portfolio of prescription medicines, vaccines and consumer products.
Why is Daiichi Sankyo developing Guardant’s companion diagnostic?
The collaboration is intended to identify patients with advanced metastatic non-small cell lung cancer for treatment with Enhertu. That links diagnostic selection directly to the addressable use of the therapy.
How do Lulu and Loxonin S change Daiichi Sankyo’s business mix?
Lulu and Loxonin S give Daiichi Sankyo consumer health exposure alongside prescription medicines. Transino, Minon and oral-care brands broaden that presence further, making the group more diversified than an oncology-only developer.
What is the DSKYF stock price today?
The last price recorded for Daiichi Sankyo Company, Limited (DSKYF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 14 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com